These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20378354)

  • 1. Successful treatment of post-stroke apathy by the dopamine receptor agonist ropinirole.
    Kohno N; Abe S; Toyoda G; Oguro H; Bokura H; Yamaguchi S
    J Clin Neurosci; 2010 Jun; 17(6):804-6. PubMed ID: 20378354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom.
    Czernecki V; Schüpbach M; Yaici S; Lévy R; Bardinet E; Yelnik J; Dubois B; Agid Y
    Mov Disord; 2008 May; 23(7):964-969. PubMed ID: 18398913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of ropinirole on apathy and depression after herpes encephalitis.
    Kohno N; Nabika Y; Toyoda G; Bokura H; Nagata T; Yamaguchi S
    Cogn Behav Neurol; 2012 Jun; 25(2):98-102. PubMed ID: 22596109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonists can improve pure apathy associated with lesions of the prefrontal-basal ganglia functional system.
    Blundo C; Gerace C
    Neurol Sci; 2015 Jul; 36(7):1197-201. PubMed ID: 25876742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
    Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
    Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropinirole in the treatment of restless legs syndrome.
    Kakar RS; Kushida CA
    Expert Rev Neurother; 2005 Jan; 5(1):35-42. PubMed ID: 15853472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
    Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ropinirol: a new dopamine agonist in the treatment of Parkinson's disease].
    Giménez-Roldán S
    Neurologia; 1997 Oct; 12(8):354-61. PubMed ID: 9471165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
    Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
    Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
    Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole: new indication. Restless legs: disproportionate adverse effects.
    Prescrire Int; 2006 Oct; 15(85):173-6. PubMed ID: 17128523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
    Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
    Makumi CW; Asgharian A; Ellis J; Shaikh S; Jimenez T; VanMeter S
    Int J Neurosci; 2016; 126(1):30-8. PubMed ID: 25495896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropinirole in restless leg syndrome.
    Ahmed I
    Mo Med; 2002; 99(9):500-1. PubMed ID: 12462942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.